alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Molecular Plant Pathology Laboratory: Beltsville, MD
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                People

                    Staff Listing
                                    Careers


        


                    Databases
                        Alfalfa Transcription Factor Database
                                    iPhyClassifier - Phytoplasma Sequence ClassificationSearch small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us




ARS Home Northeast Area Beltsville, Maryland (BARC) Beltsville Agricultural Research Center Molecular Plant Pathology Laboratory People Anna Smigocki





- Find a person
- Find a location
- ARS Organizational Chart
- People
- Con Baker
- Wei Wei
- Rosemarie Hammond
- Robert Davis
- John Hartung
- Ing Ming Lee
- Lev Nemchinov
- Anna Smigocki
- Yan Zhao
- The sugarbeet root maggot
- Reporter gene (uidA) in leaves
- Functional analysis of sugar beet resistance genes
- In vitro bioassay
- Cytokinin gene (ipt) mediated insect resistance
- Cytokinin-responsive genes
- Plant cytochrome P450 monooxygenases

<i>In vitro </i>assayheadline bar picture of sugarbeet root maggot bioassay An *in vitro* bioassay has been developed for screening sugarbeet germplasm for resistance to the root maggot.


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov
### TEXAS COURT OF APPEALS, THIRD DISTRICT, AT AUSTIN

JUDGMENT RENDERED AUGUST 19, 2022

NO. 03

- 21

- 00244

- CV

Appellant, Richard Witt Duncan// Cross

- Appellants, Prewett Rentals Series 2 752 Military,

LLC
, Tami Jan, Ward Galbreath, Sumit Kapoor, Rachel Kapo o r, Nakul Jeirath, Tasha Jeirath, Mark L. Reis, Janis R. Reis, Charles A. Bess, Jr., Dancee D. Bess, Christopher Bellshaw, Catherine Bellshaw, Santos S. Salinas, and Debra Salinas , Appellant

v.

Appellees, Prewett Rentals Series 2 752 Military, LLC
, Tami J an, Ward Galbreath, Sumit Kapoor, Rachel Kapoor, Nakul Jeirath, Tasha Jeirath, Mark L. Reis, Janis R. Reis, Charles A. Bess, Jr., Dancee D. Bess, Christopher Bellshaw, Catherine Bellshaw, Santos S. Salinas, and Debra Salinas// Cross

- Appellee, Richard Witt Duncan , Appellee

APPEAL FROM THE 433RD DISTRICT COURT OF COMAL COUNTY

BEFORE CHIEF JUSTICE BYRNE, JUSTICES TRIANA AND KELLY
AFFIRMED

-- OPINION BY JUSTICE TRIANA

This is an appeal from the order signed by the tr i a l court on June 28 , 2021

. Having reviewed the

record and the parties’ arguments, the C ourt holds that there was no reversible error in the trial

court’s order

. Therefore, t he C ourt affirms the trial court’s order

. Each party shall pay the costs

of the appeal incurred by that party, both in this Court and in the court below.
**Exhibit 12 (b)****CERTIFICATION PURSUANT TO SECTION 302(A) OF THE SARBANES-OXLEY ACT OF 2002**I, Phil Baker, certify that: 1. I have reviewed this annual report on Form 20-F of Lihir Gold Limited (the “company”);  2. Based on my knowledge, this report does not contain any untrue statement of a materialfact or omit to state a material fact necessary to make the statements made, in light ofthe circumstances under which such statements were made, not misleading with respect to theperiod covered by this report;  3. Based on my knowledge, the financial statements, and other financial informationincluded in this report, fairly present in all material respects the financial condition,results of operations and cash flows of the company as of, and for, the periods presentedin this report;  4. The company’s other certifying officer(s) and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) and internal control over financial reporting (as defined in Exchange ActRules 13a-15(f) and 15d-15(f)) for the company and have: a. Designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, to ensurethat material information relating to the company, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report is being prepared;  b. Designed such internal control over financial reporting, or caused suchinternal control over financial reporting to be designed under our supervision, toprovide reasonable assurance regarding the reliability of financial reporting andthe preparation of financial statements for external purposes in accordance withgenerally accepted accounting principles;  c. Evaluated the effectiveness of the company’s disclosure controls andprocedures and presented in this report our conclusions about the effectiveness ofthe disclosure controls and procedures, as of the end of the period covered by thisreport based on such evaluation; and  d. Disclosed in this report any change in the company’s internal controlover financial reporting that occurred during the period covered by the annualreport that has materially affected, or is reasonably likely to materially affect,the company’s internal control over financial reporting; and 5. The company’s other certifying officer(s) and I have disclosed, based on our mostrecent evaluation of internal control over financial reporting, to the company’s auditorsand the audit committee of the company’s board of directors (or persons performing theequivalent functions): a. All significant deficiencies and material weaknesses in the design oroperation of internal control over financial reporting which are reasonably likelyto adversely affect the company’s ability to record, process, summarize and reportfinancial information; and  b. Any fraud, whether or not material, that involves management or otheremployees who have a significant role in the company’s internal control overfinancial reporting.   /s/ Phil Baker Chief Financial Officer   Dated: April 18, 2007
# Official Journal L 24/2016

| | ISSN 1977-0677 |
| --- | --- |
| Official Journal
  of the European Union | L 24 |
| | |
| English edition | Legislation | Volume 5930 January 2016 |

ISSN 1977-0677

Official Journal

of the European Union

L 24

English edition

Legislation

Volume 5930 January 2016

---

| Contents | | II   Non-legislative acts | page |
| --- | --- | --- | --- |
| | | REGULATIONS |
| | * | Commission Implementing Regulation (EU) 2016/124 of 29 January 2016 approving PHMB (1600; 1.8) as an existing active substance for use in biocidal products for product-type 4 (
  1
  ) | 1 |
| | * | Commission Implementing Regulation (EU) 2016/125 of 29 January 2016 approving PHMB (1600; 1.8) as an existing active substance for use in biocidal products for product-types 2, 3, 11 (
  1
  ) | 6 |
| | | Commission Implementing Regulation (EU) 2016/126 of 29 January 2016 establishing the standard import values for determining the entry price of certain fruit and vegetables | 12 |

Contents

II   Non-legislative acts

page

REGULATIONS

*

Commission Implementing Regulation (EU) 2016/124 of 29 January 2016 approving PHMB (1600; 1.8) as an existing active substance for use in biocidal products for product-type 4 (
  1
  )

1

1

*

Commission Implementing Regulation (EU) 2016/125 of 29 January 2016 approving PHMB (1600; 1.8) as an existing active substance for use in biocidal products for product-types 2, 3, 11 (
  1
  )

1

6

Commission Implementing Regulation (EU) 2016/126 of 29 January 2016 establishing the standard import values for determining the entry price of certain fruit and vegetables

12

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | Acts whose titles are printed in light type are those relating to day-to-day management of agricultural matters, and are generally valid for a limited period.
  The titles of all other Acts are printed in bold type and preceded by an asterisk. |
| --- | --- |

EN

Acts whose titles are printed in light type are those relating to day-to-day management of agricultural matters, and are generally valid for a limited period.

The titles of all other Acts are printed in bold type and preceded by an asterisk.
<TABLE> <S> <C>

<ARTICLE> CT
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          SEP-28-1997
<PERIOD-START>                             DEC-30-1996
<PERIOD-END>                               MAR-30-1997
<TOTAL-ASSETS>                                 204,166
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                      19,570
<TOTAL-LIABILITY-AND-EQUITY>                   204,166
<TOTAL-REVENUES>                               132,878
<INCOME-TAX>                                     1,390
<INCOME-CONTINUING>                              2,362
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     2,362
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
<PAGE>   1
                                                                   EXHIBIT 23.1

                        CONSENT OF INDEPENDENT AUDITORS



We consent to the incorporation by reference in the Registration Statement
(Form S-8 No. 33-80325) pertaining to the CORESTAFF, Inc. 1995 Long-Term
Incentive Plan and in the Registration Statement (Form S-8 No. 333-3030)
pertaining to the CORESTAFF, Inc. Employee Stock Purchase Plan of our report
dated February 5, 1997, with respect to the consolidated financial statements
of CORESTAFF, Inc. included in the Annual Report (Form 10-K) for the year ended
December 31, 1996.




                                                  ERNST & YOUNG LLP


Houston, Texas
March 27, 1997
U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Nat'l Clonal Germplasm Rep - Tree Fruit & Nut Crops & Grapes: Davis, CA
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                People

                    Staff Listing
                                    Careers


        


                    Orders & ServicesSearch small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us






Order Formheadline bar PandP


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov
**Exhibit 10.22**

 

AMENDMENT 

TO

AMENDED AND RESTATED CAREMARK RX, INC. 1993 STOCK OPTION PLAN 

EFFECTIVE NOVEMBER 15, 2000 

 

The Amended and Restated Caremark Rx, Inc. 1993 Stock Option Plan (the “Plan”) is hereby amended as follows: 

 

1. Amendment Regarding Transferability of Nonqualified Stock Options. Section 6.1(e)(2) of the Plan is hereby amended by deletingSection 6.1(e)(2) in its entirety and substituting the following new Section 6.1(e)(2) therefor: 

 

(2) Nonqualified Stock Options. No NQO granted under the Plan may be sold, transferred, pledged, assigned, or otherwise alienated orhypothecated, other than by will or by the laws of descent and distribution. Notwithstanding the foregoing, to the extent not prohibited by any statute, rule or regulation applicable to the Plan, the Options or the registration with the Securitiesand Exchange Commission of the Common stock to be issued upon exercise of the Option, the Committee may, in its discretion, authorize all or a portion of NQOs granted to an optionee to be on terms which permit transfer by such optionee to(i) the spouse, children or grandchildren of the optionee (“Immediate Family Members”), (ii) a trust or trusts for the exclusive benefit of such Immediate Family Members, or (iii) a partnership in which such Immediate FamilyMembers are the only partners, provided that (y) the Option Agreement pursuant to which such NQOs are granted must be approved by the Committee, and must expressly provide for transferability in a manner consistent with this Section, and(z) subsequent transfers of transferred NQOs shall be prohibited except those by will or the laws of descent and distribution. Following transfer, any such NQOs shall continue to be subject to the same terms and conditions as were applicableimmediately prior to transfer, provided that for purposes of this Plan, the term “optionee” shall be deemed to refer to the transferee. The events of termination of employment shall continue to be applied with respect to the original

 

1 

optionee, following which the NQOs shall be exercised by the transferee only to the extent, and for theperiods specified in Section 6.1(g). Notwithstanding the foregoing, should the Committee provide that NQOs granted be transferable, the Company by such action incurs no obligation to notify or otherwise provide notice to a transferee of earlytermination of the NQO. In the event of a transfer, as set forth above, the original optionee is and will remain subject to an responsible for any applicable withholding taxes upon the exercise of such NQOs. 

 

2. Effective Date. The effective date of this Amendment shall beNovember 15, 2000. 

 

3. Miscellaneous. 

 

(a) Capitalized terms not otherwise defined herein shall have the meaningsgiven them in the Plan. 

 

(b) Except as specifically amendedhereby, the Plan shall remain in full force and effect. 

 

INWITNESS WHEREOF, the Company has caused this Amendment to the Amended and Restated Caremark Rx, Inc. 1993 Stock Option Plan to be executed as of the Effective Date. 

 

CAREMARK RX, INC.

Sara J. Finley, Corporate Secretary

 

2
<PAGE>

                                                                    Exhibit 24.1

                                POWER OF ATTORNEY

         WHEREAS, the undersigned officers and directors of CD&L, Inc. (the
"Company") desire to authorize Albert W. Van Ness, Jr., and William T. Brannan
to act as their attorneys-in-fact and agents, for the purpose of executing and
filing the Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2004, including all amendments thereto;

         NOW, THEREFORE,

         KNOW ALL MEN BY THESE PRESENTS, that each person whose signature
appears below constitutes and appoints Albert W. Van Ness, Jr., and William T.
Brannan and each of them, his true and lawful attorney-in-fact and agent, with
full power of substitution and re-substitution, to execute the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2004, including any
and all amendments and supplements thereto, and to file the same, with all
exhibits thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorneys-in-fact and
agents, and each of them, full power and authority to do and perform each and
every act and thing requisite and necessary to be done in and about the
premises, as fully and to all intents and purposes as he might or could do in
person, hereby ratifying and confirming all that said attorneys-in-fact and
agents, or any of them, or their or his substitute or substitutes, may lawfully
do or cause to be done by virtue hereof.

         IN WITNESS WHEREOF, the undersigned have executed this power of
attorney in the following capacities as of the 15th day of April 2005.

         SIGNATURE                     TITLE
         ---------                     -----

/s/ Albert W. Van Ness, Jr.   Chairman of the Board, Chief Executive Officer and
---------------------------   Director (Principal Executive Officer)
Albert W. Van Ness, Jr.

/s/ William T. Brannan        President, Chief Operating Officer and Director
----------------------
William T. Brannan

/s/ Russell J. Reardon        Vice President, Chief Financial Officer (Principal
----------------------        Financial and Accounting Officer)
Russell J. Reardon

/s/ Michael Brooks            Group Operations President and Director
------------------
Michael Brooks

/s/ Thomas E. Durkin          Director
--------------------
Thomas E. Durkin

/s/ Jon F. Hanson             Director
-----------------
Jon F. Hanson

/s/ Marilu Marshall           Director
-------------------
Marilu Marshall

/s/ Matthew Morahan           Director
-------------------
Matthew Morahan

/s/ John Simourian            Director
------------------
John Simourian

/s/ John S. Wehrle            Director
------------------
John S. Wehrle
**Exhibit 31.1**

**CERTIFICATION**

I, Robert H. Gilliam, Jr., certify that: 

1. I have reviewed this report on Form 10-Q of Pinnacle Bankshares Corporation; 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of theregistrant as of, and for, the periods presented in this report; 

4. The registrant’s other certifying officer and I are responsiblefor establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, includingits consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

(b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the endof the period covered by this report based on such evaluation; and 

(c) Disclosed in this report any change in the registrant’sinternal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely tomaterially affect, the registrant’s internal control over financial reporting; and 

5. The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonablylikely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and 

(b) Anyfraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. 

Date: November 10, 2006 

 

/s/ Robert H. Gilliam, Jr.

Robert H. Gilliam, Jr.,

President and Chief ExecutiveOfficer
Exhibit 23.1 

 

INDEPENDENT AUDITORS’ CONSENT 

 

We consent to the incorporation by reference in the Registration Statements of Internet America, Inc., on Form S-8 (Nos. 333-70461, 333-72109, 333-72111, 333-77153,333-80277, 355-80285, and 333-92295) of our report dated September 3, 2003 (which report expresses an unqualified opinion and includes an explanatory paragraph relating to the Company’s change in its method of accounting for goodwill),appearing in the Annual Report on Form 10-K of Internet America, Inc., for the year ended June 30, 2003. 

 

DELOITTE & TOUCHE LLP 

 

Dallas, Texas 

September 29, 2003